Literature DB >> 22733106

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma.

H Tilly, F Morschhauser, G Salles, R-O Casasnovas, P Feugier, T J Molina, F Jardin, L Terriou, C Haioun, B Coiffier.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22733106     DOI： 10.1038/leu.2012.172

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 2.  A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma.

Authors:  Mili Arora; Sonia Gowda; Joseph Tuscano
Journal:  Ther Adv Hematol       Date:  2016-07-01

Review 3.  IMiDs New and Old.

Authors:  Samuel Yamshon; Jia Ruan
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 4.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

5.  Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.

Authors:  Annalisa Chiappella; Alessandra Tucci; Alessia Castellino; Vincenzo Pavone; Ileana Baldi; Angelo Michele Carella; Lorella Orsucci; Manuela Zanni; Flavia Salvi; Anna Marina Liberati; Gianluca Gaidano; Chiara Bottelli; Bernardo Rossini; Sonia Perticone; Pasqualina De Masi; Marco Ladetto; Giovannino Ciccone; Antonio Palumbo; Giuseppe Rossi; Umberto Vitolo
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

6.  Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.

Authors:  Marie-Hélène Delfau-Larue; Axel van der Gucht; Jehan Dupuis; Jean-Philippe Jais; Isabelle Nel; Asma Beldi-Ferchiou; Salma Hamdane; Ichrafe Benmaad; Gaelle Laboure; Benjamin Verret; Corinne Haioun; Christiane Copie-Bergman; Alina Berriolo-Riedinger; Philippine Robert; René-Olivier Casasnovas; Emmanuel Itti
Journal:  Blood Adv       Date:  2018-04-10

7.  Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.

Authors:  Samuel Yamshon; Paul J Christos; Michelle Demetres; Hoda Hammad; John P Leonard; Jia Ruan
Journal:  Blood Adv       Date:  2018-06-26

Review 8.  Novel CD20 monoclonal antibodies for lymphoma therapy.

Authors:  Shundong Cang; Nikhil Mukhi; Kemeng Wang; Delong Liu
Journal:  J Hematol Oncol       Date:  2012-10-11       Impact factor: 17.388

Review 9.  Lymphoma: immune evasion strategies.

Authors:  Ranjan Upadhyay; Linda Hammerich; Paul Peng; Brian Brown; Miriam Merad; Joshua D Brody
Journal:  Cancers (Basel)       Date:  2015-04-30       Impact factor: 6.639

10.  Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.

Authors:  Jiangning Zhao; Zhenshu Xu; Delong Liu; Quanyi Lu
Journal:  Cancer Cell Int       Date:  2012-08-23       Impact factor: 5.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.